Objective: The aim of this study was to verify the serum GDNF levels in individuals with anxiety disorder (AD) in a population-based study.
Methods: This was a cross-sectional study population-based, with people aged 18 to 35. AD's assessment was performed using the Mini International Neuropsychiatric Interview (M.I.N.I). Serum GDNF was measured by ELISA using a commercial kit.
Results: The prevalence was 3.3% for post-traumatic stress disorder, 6.7% for panic disorders, 17% generalized anxiety disorder, 5.1% for obsessive- compulsive disorder and 7.5% for social phobia. Serum GDNF levels was higher in individuals with panic disorders (p = 0.013), generalized anxiety (p = 0.035), obsessive- compulsive disorder (p = 0.005) and social phobia (p = 0.004), when compared to individuals without ADs. Only post traumatic stress disorder is not associated with serum GDNF levels (p = 0.119).
Conclusion: In this paper, we observed increased serum levels of GDNF in individuals with anxiety disorders, suggesting that this biomarker can be used as a putative marker for AD's. The knowledge of the physiological changes related to anxiety disorders can provide a better understanding of AD's pathogenesis, as well as, mechanisms involved in the progression of this condition.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.cca.2018.06.017 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Glial Derived Neurotrophic Factor and Schizophrenia Spectrum Disorders: A Scoping Review.
Curr Neuropharmacol
December 2024
Ospedale San Luigi Gonzaga, Università degli Studi di Torino, Italia; Regione Gonzole, 10, Orbassano 10043, Torino, Italia.
Background: Psychotic disorders, characterized by altered brain function, significantly impair reality perception. The neurodevelopmental hypothesis suggests these disorders originate from early brain development disruptions. Glial-derived neurotrophic factor (GDNF) is crucial for neuronal survival and differentiation, especially in dopaminergic neurons, and shows promise in neurodegenerative and neuropsychiatric conditions.
View Article and Find Full Text PDFGDF15-GFRAL signaling drives weight loss and lipid metabolism in mouse model of amyotrophic lateral sclerosis.
Brain Behav Immun
December 2024
Department of Physiology and Pharmacology, Sapienza University of Rome, Rome, Italy; IRCCS Neuromed, Pozzilli, Italy. Electronic address:
Weight loss is a common early sign in amyotrophic lateral sclerosis (ALS) patients and negatively correlates with survival. In different cancers and metabolic disorders, high levels of serum growth differentiation factor 15 (GDF15) contribute to a decrease of food intake and body weight, acting through GDNF family receptor alpha-like (GFRAL). Here we report that GDF15 is highly expressed in the peripheral blood of ALS patients and in the hSOD1 mouse model and that GFRAL is upregulated in the brainstem of hSOD1 mice.
View Article and Find Full Text PDFNeuroprotective Effect of Maresin-1 in Rotenone-Induced Parkinson's Disease in Rats: The Putative Role of the JAK/STAT Pathway.
Neurochem Res
November 2024
Medical Physiology Department, Faculty of Medicine, Menoufia University, Menoufia, 32511, Egypt.
Exposure to rotenone results in similar pathophysiological features as Parkinson's disease. Inflammation and oxidative stress are essential to PD pathogenesis. Maresin-1 has potent anti-inflammatory properties and promotes the regression of inflammation function.
View Article and Find Full Text PDFCandidate serum protein biomarkers for active pulmonary tuberculosis diagnosis in tuberculosis endemic settings.
BMC Infect Dis
November 2024
Armauer Hansen Research Institute, Addis Ababa, Ethiopia.
Background: Identification of non-sputum diagnostic markers for tuberculosis (TB) is urgently needed. This exploratory study aimed to discover potential serum protein biomarkers for the diagnosis of active pulmonary TB (PTB).
Method: We employed Proximity Extension Assay (PEA) to measure levels of 92 protein biomarkers related to inflammation in serum samples from three patient groups: 30 patients with active PTB, 29 patients with other respiratory diseases with latent TB (ORD with LTBI+), and 29 patients with other respiratory diseases without latent TB (ORD with LTBI-).
Prediction model of male reproductive function damage caused by CHOP chemotherapy regimen for non-Hodgkin's lymphoma.
BMC Cancer
November 2024
Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an City, Shanxi Province, 710049, China.
Objective: The CHOP combined chemotherapy regimen (cyclophosphamide, doxorubicin, vincristine, and prednisone) is commonly used to treat non-Hodgkin Lymphoma (NHL). While these drugs are effective for cancer treatment, they may have side effects on the reproductive system that are poorly studied. This study used a mouse model to investigate the mechanisms of reproductive function impairment induced by the CHOP regimen and developed a predictive model for assessing reproductive damage with a non-invasive procedure.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!